Vanguard Group’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $226M | Sell |
17,907,815
-47,158
| -0.3% | -$540K | ﹤0.01% | 1488 |
|
|
2025
Q3 | $180M | Buy |
17,954,973
+403,582
| +2% | +$3.62M | ﹤0.01% | 1591 |
|
|
2025
Q2 | $142M | Buy |
17,551,391
+1,788,664
| +11% | +$13.5M | ﹤0.01% | 1671 |
|
|
2025
Q1 | $132M | Buy |
15,762,727
+920,758
| +6% | +$7.69M | ﹤0.01% | 1669 |
|
|
2024
Q4 | $118M | Buy |
14,841,969
+218,025
| +1% | +$1.83M | ﹤0.01% | 1801 |
|
|
2024
Q3 | $122M | Buy |
14,623,944
+629,766
| +5% | +$4.92M | ﹤0.01% | 1782 |
|
|
2024
Q2 | $88.9M | Buy |
13,994,178
+265,945
| +2% | +$1.69M | ﹤0.01% | 1889 |
|
|
2024
Q1 | $83.2M | Buy |
13,728,233
+85,846
| +0.6% | +$484K | ﹤0.01% | 1956 |
|
|
2023
Q4 | $82.8M | Buy |
13,642,387
+94,087
| +0.7% | +$419K | ﹤0.01% | 1953 |
|
|
2023
Q3 | $57.2M | Buy |
13,548,300
+412,599
| +3% | +$1.54M | ﹤0.01% | 2067 |
|
|
2023
Q2 | $40.7M | Sell |
13,135,701
-141,715
| -1% | -$302K | ﹤0.01% | 2279 |
|
|
2023
Q1 | $18.5M | Buy |
13,277,416
+229,348
| +2% | +$457K | ﹤0.01% | 2616 |
|
|
2022
Q4 | $26M | Buy |
13,048,068
+213,723
| +2% | +$479K | ﹤0.01% | 2502 |
|
|
2022
Q3 | $25.9M | Buy |
12,834,345
+181,885
| +1% | +$510K | ﹤0.01% | 2519 |
|
|
2022
Q2 | $40.2M | Sell |
12,652,460
-177,912
| -1% | -$645K | ﹤0.01% | 2296 |
|
|
2022
Q1 | $53.5M | Buy |
12,830,372
+1,255,477
| +11% | +$5.56M | ﹤0.01% | 2269 |
|
|
2021
Q4 | $55.4M | Buy |
11,574,895
+315,036
| +3% | +$1.57M | ﹤0.01% | 2290 |
|
|
2021
Q3 | $60.1M | Sell |
11,259,859
-236,808
| -2% | -$1.19M | ﹤0.01% | 2261 |
|
|
2021
Q2 | $58.9M | Buy |
11,496,667
+391,756
| +4% | +$2.23M | ﹤0.01% | 2278 |
|
|
2021
Q1 | $74.7M | Buy |
11,104,911
+122,080
| +1% | +$677K | ﹤0.01% | 2103 |
|
|
2020
Q4 | $50.2M | Buy |
10,982,831
+216,548
| +2% | +$960K | ﹤0.01% | 2201 |
|
|
2020
Q3 | $41.8M | Sell |
10,766,283
-468,689
| -4% | -$2M | ﹤0.01% | 2104 |
|
|
2020
Q2 | $53.5M | Buy |
11,234,972
+493,568
| +5% | +$2.03M | ﹤0.01% | 1982 |
|
|
2020
Q1 | $37.4M | Buy |
10,741,404
+556,329
| +5% | +$2.36M | ﹤0.01% | 1996 |
|
|
2019
Q4 | $49.1M | Buy |
10,185,075
+715,341
| +8% | +$2.49M | ﹤0.01% | 2114 |
|
|
2019
Q3 | $27.5M | Sell |
9,469,734
-287,894
| -3% | -$1M | ﹤0.01% | 2321 |
|
|
2019
Q2 | $70M | Buy |
9,757,628
+218,497
| +2% | +$2.23M | ﹤0.01% | 1939 |
|
|
2019
Q1 | $135M | Buy |
9,539,131
+434,069
| +5% | +$5.74M | 0.01% | 1581 |
|
|
2018
Q4 | $123M | Sell |
9,105,062
-102,916
| -1% | -$1.85M | 0.01% | 1554 |
|
|
2018
Q3 | $204M | Buy |
9,207,978
+465,375
| +5% | +$9.79M | 0.01% | 1370 |
|
|
2018
Q2 | $143M | Buy |
+8,742,603
| New | +$153M | 0.01% | 1574 |
|
Other funds holding AMRX
RCMNY
TGA
Vanguard Group's AMRX Position: Q4 2025 in Review
Vanguard Group reduced its Amneal Pharmaceuticals (AMRX) stake by 0.26% in Q4 2025, selling an estimated $540K and leaving 17,907,815 shares worth $226M. The position accounts for ﹤0.01% of the portfolio, ranked #1488.
Vanguard Group first reported a position in AMRX in Q2 2018 and has held it in 31 quarters since. 277 funds tracked by Wall St. Rank hold AMRX as of Q4 2025.
- Vanguard Group held 17,907,815 shares of Amneal Pharmaceuticals worth $226M as of Q4 2025.
- Vanguard Group sold 47,158 Amneal Pharmaceuticals shares in Q4 2025, an estimated $540K.
- Amneal Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1488 holding.
- Vanguard Group first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
- 277 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.